RR and AR of second malignancies by sites in all 1319 patients
| Second malignancy . | O . | E . | RR . | (95% CI) . | AR . |
|---|---|---|---|---|---|
| All sites | 181 | 38.97 | 4.6 | (4.0, 5.4) | 89.3 |
| Acute leukemia | 23 | 0.28 | 82.5 | (53.5, 122.2) | 14.3 |
| Non-Hodgkin lymphoma | 24 | 1.46 | 16.5 | (10.2, 23.8) | 14.2 |
| Multiple myeloma | 3 | 0.32 | 9.4 | (1.9, 27.4) | 1.7 |
| Solid tumors | 131 | 36.91 | 3.5 | (3.0, 4.2) | 59.1 |
| Breast | 39 | 5.83 | 6.7 | (4.8, 8.9) | 20.8 |
| Lung | 22 | 4.53 | 4.9 | (3.0, 7.1) | 11.0 |
| Gastrointestinal | 24 | 5.96 | 4.0 | (2.5, 5.8) | 11.3 |
| Sarcoma | 11 | 0.41 | 26.6 | (13.3, 47.6) | 6.7 |
| Genitourinary | 11 | 6.07 | 1.8 | (0.9, 3.2) | 3.1 |
| Head and neck | 7 | 1.75 | 4.0 | (1.6, 8.2) | 3.3 |
| Melanoma | 7 | 2.14 | 3.3 | (1.3, 6.7) | 3.1 |
| Thyroid | 5 | 0.89 | 5.6 | (1.8, 13.0) | 2.6 |
| Gynecological | 4 | 8.58 | 0.5 | (0.1, 1.2) | − 2.9 |
| Central nervous system | 1 | 0.74 | 1.4 | (0.04, 7.5) | 0.2 |
| Second malignancy . | O . | E . | RR . | (95% CI) . | AR . |
|---|---|---|---|---|---|
| All sites | 181 | 38.97 | 4.6 | (4.0, 5.4) | 89.3 |
| Acute leukemia | 23 | 0.28 | 82.5 | (53.5, 122.2) | 14.3 |
| Non-Hodgkin lymphoma | 24 | 1.46 | 16.5 | (10.2, 23.8) | 14.2 |
| Multiple myeloma | 3 | 0.32 | 9.4 | (1.9, 27.4) | 1.7 |
| Solid tumors | 131 | 36.91 | 3.5 | (3.0, 4.2) | 59.1 |
| Breast | 39 | 5.83 | 6.7 | (4.8, 8.9) | 20.8 |
| Lung | 22 | 4.53 | 4.9 | (3.0, 7.1) | 11.0 |
| Gastrointestinal | 24 | 5.96 | 4.0 | (2.5, 5.8) | 11.3 |
| Sarcoma | 11 | 0.41 | 26.6 | (13.3, 47.6) | 6.7 |
| Genitourinary | 11 | 6.07 | 1.8 | (0.9, 3.2) | 3.1 |
| Head and neck | 7 | 1.75 | 4.0 | (1.6, 8.2) | 3.3 |
| Melanoma | 7 | 2.14 | 3.3 | (1.3, 6.7) | 3.1 |
| Thyroid | 5 | 0.89 | 5.6 | (1.8, 13.0) | 2.6 |
| Gynecological | 4 | 8.58 | 0.5 | (0.1, 1.2) | − 2.9 |
| Central nervous system | 1 | 0.74 | 1.4 | (0.04, 7.5) | 0.2 |
O indicates observed; E, expected; RR, relative risk; CI, confidence interval; AR, absolute excess risk.